Mosotex Profi

Hauptinformation

  • Handelsname:
  • Mosotex Profi
  • Darreichungsform:
  • WG Wasserdispergierbares Granulat
  • Verwenden für:
  • Pflanzen
  • Art der Medizin:
  • Agrochemisch

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Mosotex Profi
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Herbizid

Weitere Informationen

Status

  • Quelle:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Zulassungsnummer:
  • W-5813-2
  • Letzte Änderung:
  • 15-11-2018

Packungsbeilage

Handelsbezeichnung: Mosotex Profi

Pflanzenschutzmittelverzeichnis (Stand: 06.11.2018)

Produktkategorie:

Bewilligungsinhaber:

Eidg. Zulassungsnummer:

Herbizid

Syngenta Agro AG

W-5813-2

Stoff(e):

Gehalt:

Formulierungscode:

Wirkstoff: Quinoclamine 50 %

WG Wasserdispergierbares Granulat

Anwendungen

A

Kultur

Schaderreger/

Wirkung

Dosierungshinweise

Auflagen

Bäume und Sträucher (ausserhalb

Forst)

Blumenkulturen und Grünpflanzen

Rosen

Lebermoose

Aufwandmenge: 7.5 kg/ha 1, 2

Z Zier- und Sportrasen

Moose (Bryophyta)

Aufwandmenge: 7.5 kg/ha 1, 2

Auflagen und Bemerkungen:

Nachfolgearbeiten in behandelten Kulturen: bis 48 Stunden nach Ausbringung des Mittels

Schutzhandschuhe + Schutzanzug tragen.

Ansetzen der Spritzbrühe: Schutzhandschuhe + Schutzanzug + Schutzbrille oder Visier tragen.

Ausbringen der Spritzbrühe: Schutzhandschuhe + Schutzanzug tragen. Technische

Schutzvorrichtungen während des Ausbringens (z.B. geschlossene Traktorkabine) können die

vorgeschriebene persönliche Schutzausrüstung ersetzen, wenn gewährleistet ist, dass sie einen

vergleichbaren oder höheren Schutz bieten.

Gefahrenkennzeichnungen:

Darf nicht in die Hände von Kindern gelangen.

EUH 401 Zur Vermeidung von Risiken für Mensch und Umwelt die Gebrauchsanleitung

einhalten.

H319 Verursacht schwere Augenreizung.

H361 Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen.

H373 Kann die Organe schädigen bei längerer oder wiederholter Exposition.

H400 Sehr giftig für Wasserorganismen.

H410 Sehr giftig für Wasserorganismen mit langfristiger Wirkung.

SP 1 Mittel und/oder dessen Behälter nicht in Gewässer gelangen lassen.

Signalwort:

Achtung

Gefahrensymbole und -bezeichnungen:

Kurzkennzeichnung

GHS07

GHS08

GHS09

Symbol

Gefahrenbezeichnung Vorsicht gefährlich Gesundheitsschädigend Gewässergefährdend

Im Zweifelsfall gelten einzig die Originaldokumente der Zulassung. Die Erwähnung eines Produktes,

Wirkstoffes oder einer Firma stellt keine Empfehlung dar und bedeutet nicht, dass sich das Produkt im

Verkauf befindet.

9-11-2018

Sargassum seaweed: limit the exposure of residents and workers to hydrogen sulphide

Sargassum seaweed: limit the exposure of residents and workers to hydrogen sulphide

Since August 2014, the French Caribbean and French Guiana have been experiencing successive waves of Sargassum seaweed washing up on their coastlines. Despite the efforts made to clean it up, the seaweed decomposes in situ. This leads to the production of hydrogen sulphide (H2S), which can sometimes be detected at high concentrations. Doctors' reports concerning the health effects suffered by people exposed to H2S, and complaints from the general public relating to the problem of odours, have increased s...

France - Agence Nationale du Médicament Vétérinaire

28-9-2018

Debate on research dissemination at the Danish Medicines Agency

Debate on research dissemination at the Danish Medicines Agency

On 1 October, the Danish Medicines Agency and the Danish Society for Pharmacoepidemiology have invited a number of researchers, doctors and communication officers from research institutions throughout Denmark to a debate on how the findings of new health research can be disseminated most responsibly. The debate meeting can be followed live on the Danish Medicines Agency’s Facebook profile.

Danish Medicines Agency

11-9-2018

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Novel foods: a risk profile for the house cricket (Acheta domesticus)

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Novel foods could represent a sustainable alternative to traditional farming and conventional foodstuffs. Starting in 2018, Regulation (EU) 2283/2015 entered into force, laying down provisions for the approval of novel foods in Europe, including insects. This Approved Regulation establishes the requirements that enable Food Business Operators to bring new foods into the EU market, while ensuring high levels of food safety for European consumers. The present ...

Europe - EFSA - European Food Safety Authority Publications

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

13-6-2017

Tramadol: It is important that we are informed of side effects

Tramadol: It is important that we are informed of side effects

Doctors should contact the Danish Medicines Agency if clinical experience shows that the side-effect profile of a medicinal product is not consistent with the summary of product characteristics.

Danish Medicines Agency

9-2-2016

EMA: No changes to the safety profile of Gardasil

EMA: No changes to the safety profile of Gardasil

The European Medicines Agency (EMA) has recently completed its annual routine safety assessment of the HPV vaccine Gardasil®. The conclusion is that there are no changes to the safety profile.

Danish Medicines Agency

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency

22-7-2018

Our aim: ensure that devices not only meet the gold standard for getting to market but continue to meet this standard as we get more data and learn more about their benefit-risk profile in real-world settings. These new approaches will also help advance b

Our aim: ensure that devices not only meet the gold standard for getting to market but continue to meet this standard as we get more data and learn more about their benefit-risk profile in real-world settings. These new approaches will also help advance b

Our aim: ensure that devices not only meet the gold standard for getting to market but continue to meet this standard as we get more data and learn more about their benefit-risk profile in real-world settings. These new approaches will also help advance beneficial innovation

FDA - U.S. Food and Drug Administration

4-5-2018

Medical devices and IVDs: Cancellations from the ARTG

Medical devices and IVDs: Cancellations from the ARTG

Cancellation of Profile Surgical Forceps, biopsy

Therapeutic Goods Administration - Australia